TORONTO, July 5, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") made the following announcements:
Biosign Schedules Investor Conference Call
Biosign is pleased to announce an Investor Conference Call, scheduled
for Monday, July 15th, 2013 at 11:00 AM Eastern Daylight Time. During this call, Biosign CEO Robert Kaul will read a prepared
statement commenting on recent news releases and placing those releases
into the context of the Company's business plan. Following this
presentation, Mr. Kaul will answer a number of questions submitted in
advance in writing, regarding the business of the Company.
The conference call is open to any investor or stakeholder, including
shareholders, broker-dealers and other securities professionals. The
call will be recorded and available for review at
http://biosign.com/investors. To submit one or more questions to the
CEO, please email your question to firstname.lastname@example.org with the words "Investor Question for Conference Call" in the subject
line. Biosign management will endeavour to address as many questions as
possible in the one-hour allocated to the call. To participate in the
call, please use the following login credentials:
Dial-In Number: 877-394-5901 Participant Code: 2169148
Biosign CEO Robert Kaul stated, "In the last several weeks, Biosign has
made a number of material announcements related to our business plan.
Management is pleased to be able to communicate with investors and
other interested parties in order to place these announcements into
greater context, and to address various stakeholder inquiries."
Biosign Partially Converts Debenture
The Company has received and processed a "Notice of Election to Convert"
a portion of the Debenture issued to BioAnalytics Inc. under the terms
of the Asset Purchase Agreement between the parties dated December 7th, 2012. BioAnalytics has converted $240,000 out of a total balance of
$300,000 into 2,000,000 common shares of Biosign. The shares issued are
subject to a four-month and one day hold period under applicable TSX-V
Completion of Shares for Debt Transaction - Update
On June 11th, 2013, the Company previously announced that it has entered into
agreements to convert $205,660 of indebtedness into 4,113,200 common
shares of the Company at a price of $0.05 per share. The Company wishes
to advise that such shares issued under this conversion are subject to
a four-month and one day hold period under applicable securities laws.
Biosign CEO Robert Kaul commented: "These conversions of debt into
equity are a welcome endorsement of Biosign's ability to execute our
business plan. We note in particular that such conversions were
completed at a premium to the current market price".
About Biosign Technologies Inc:
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer
enabled health information products. Key applications include the
noninvasive monitoring of vital signs including blood pressure, pulse
rate and breathing rate, enhanced with web services. The Company's
Pulsewave™ medical device technology powers data collection for
clinical decision support, self-care, wellness and disease management,
while its Healthanywhere™ software suite offers industry-leading remote
patient monitoring solutions. The Company offers a number of
cardiovascular screening programs for consumers under its Heart
Friendly™ brand, including Heart Friendly™ Dentist. For more
information on Biosign, please visit www.biosign.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Contact Information for Biosign:
Chief Executive Officer
Phone: (416) 218-9800 ext. 201